

Crimean- Congo Hemorrhagic Fever


Onder Ergonul, MD, MPH


Marmara University, School of Medicine I nf ectious Diseases Department I st anbul, Turkey


29 November 2008, Lelyst ad, Net her lands

































- Stable local foci in the nature
- Virus is circulated between ticks and wild/domestic animals
- Foci expand after ecological changes



Notification after human cases...

The Course of Infection in animals

- No clinical symptoms
 - Not known in veterinary medicine
- Viremia
 - Last s f or 7-10 days in mammals







Seropositive and/or PCR+ Animals in Turkey


- Cattle
- Sheep
- Wild boars
- Hares
- Ground feeding birds
 - Partridges etc.













The Suspected Case


- 1. I ndividuals, who had f ever, myalgia, malaise, diarrhea, and
- 2. History of being in endemic area
 - Tick exposure history and/or
 - Residency or travel to CCHF endemic region


The probable case

Pat ient's who had leukopenia, thrombocyt openia, elevat ed AST, ALT, and LDH levels.

Confirmed case

CCHF I gM of PCR positivity in the blood or body fluids of the patient.









The Predictors of Fatality

Viral factors

High viral load shown by recent studies for many VHFs

Cevik, et al. Cl D 2007

Host factors

Cyt okines: TNF alf a, IL1, IL6

Ergonul, et al. JID 2006


Why The Case Fatality Rates Are Different?


- 1) Different strains
- 2) Co-exist ent infections
- 3) Host factors
- 2) Health care facility
 - Access
 - Qualit y
- 3) Public awareness

Pat hogenesis


- Capillary fragility
 - "capillary toxicosis", Soviet scientists
 - I nf ect ion of endot helium
- Coagulopat hy
- · Multiple host induced mechanisms
 - Massive apopt osis of lymhocyt es
 - Induction of proinflammatory cytokines
 - Dysregulation of coagulation cascade
 - DIC

Geisbert TW, Nature Med 2004 10: 110-121






	Pat ient s sur vived n=50	Pat ient s died n=4
gM positives	37/40 (93)	1/4 (25)
I gG posit ivit y	27/40 (68)	0/4 (0)
PCR posit ivit y	19/40 (48)	3/4 (50)



Bone marrow aspiration smear, stained with Wright, showing

hemophagocyt osis

A) phagocytosis of an erythrocyte and nuclear remnants by a macrophage.



B) phagocytosis of platelets by a macrophage.

Karti SS, et al. Emerg Infect Dis 2004

Crimean-Congo hemorrhagic fever: Five patients with hemophagocytic syndrome

Nuriye Tasdelen Fisgin, 1* Tunc Fisgin, 2 Esra Tanyel, Levent Doganci, Necla Tulek, Nil Guler, and Feride Duru²

Department of Clinical Microbiology and Infectious Disease, Ondokuz Mayis University, Medical School, Samsun, Turkey Department of Pediatric Hematology, Ondokuz Mayis University, Medical School, Samsun, Turkey Department of Hematology, Ondokuz Mayis University, Medical School, Samsun, Turkey






Figure 5. Hemophagocytosis in the bone marrow aspiration smears in Patient 5. Am J Hemat ol 2007

Ribavirin: Only Drug for VHFs

Arenaviridae			
Lassa Fever			
South America HF			
Bunyaviridae			
Hant a			
Rift Valley			
CCHF			





Confounders in Ribavirin use

- 1. Severity
- 2. Number of Days from onset of symptoms
 - 1. Prehemorhagic
 - 2. Hemorhagic
- 3. I nef f ect ive application:
 - GIS symptoms in or al use (hemat emesis)
- 4. Duration of treatment
- 5. I nclusion criteria


Health Ca	re Worke	rs infe	ct ed by	CCHF
Count ry	Year	inf ect ed	f at al	
Bulgaria	1950-1974	42	17	
South Africa	a 1967	5	?	
	1984	7	1	
Pakist an	1976	4	2	
	1994	3	?	
	2002	2	1	
Iraq	1979	2	2	
Unit ed Ar abic Emir at es	1979	5	2	
Albania	2002	1	0	
Moritania	2003	5	5	
Turkey	2003	1 (?)	1	
	2005	3	-	
	2006	1	1	
	2008	8	1	
TOTAL		88	32	

Case Management			
Suspect ed case	Clinical symptoms History Biochemical tests		
Prevent ive measures	I solation of the patient Education of the HCWs Use or barrier precautions		
Confirmation of dgx	PCR ELI SA		
Decision for tx	Definition of severity criteria and ribavirin use Differential diagnosis and doxycycline Hematologic support Respiration support		
Follow-up	No recurrence HCWs		
	Ergönül O. Lancet I nf ect Dis 2006		

Tick removal: What is the best way?



Vat ansever Z, I n: Ergonul & Whit ehouse, Crimean-Congo Hemorrhagic Fever: A Global Perspective, Springer, 2007



Bulgarian Experience

Passive simultaneous transfer of two different specific immunoglobulin preparations,

"CCHF-bulin" (for intramuscular use) "CCHF-venin" (for intravenous use),

prepared from the plasma of CCHF survivor donors (Vassilenko et al., 1990).

Only 7 patients

Turkish Experience on CCHF

- 1. Acceleration phase of the epidemic curve: Every year, more cases than a year ago.
- 2. Dissemination of the cases to the west.
- 3. More HCWs have been effected.
 - 1. Protection of HCWs
 - 2. Infection Control in Hospitals
- 4. Debate on ribavirin use: RCT?
- 5. Personal protection
 - 1. How to remove ticks?
 - 2. Repellents, permethrine

"I was tired, and what was the use? I must have examined the stomachs of a thousand mosquitoes by this time. But the Angel of Fate fortunately laid his hand on my head"

Sir Ronald Ross, 1857-1932

How long should we wait?

Thank you